Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai To Establish U.K. Facility To Take Drugs From R&D To Market

This article was originally published in PharmAsia News

Executive Summary

Eisai is opening a facility in the United Kingdom to take drugs from research through marketing, its first production base in Europe. The $165 million site is intended to more than double the company's drug researchers, to 60, and focus on developing drugs to treat mental ailments such as dementia. In a change from outsourcing its work to Europe, Eisai has decided to use a U.K. location to do research and develop, produce drugs and market them. Eisai expects to begin packaging drugs in the current fiscal year and produce pills and powders in fiscal 2010 with a capacity of producing 400 million pills a year. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts